- Home
- ELVA vs IKT Comparison
ELVA vs IKT Comparison
Compare ELVA & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- IKT
- Stock Information
- Founded
- ELVA 1996
- IKT 2008
- Country
- ELVA Canada
- IKT United States
- Employees
- ELVA N/A
- IKT N/A
- Industry
- ELVA
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- ELVA
- IKT Health Care
- Exchange
- ELVA Nasdaq
- IKT Nasdaq
- Market Cap
- ELVA 125.5M
- IKT 131.6M
- IPO Year
- ELVA N/A
- IKT 2020
- Fundamental
- Price
- ELVA $3.30
- IKT $1.85
- Analyst Decision
- ELVA Strong Buy
- IKT Buy
- Analyst Count
- ELVA 5
- IKT 2
- Target Price
- ELVA $6.10
- IKT $8.00
- AVG Volume (30 Days)
- ELVA 87.3K
- IKT 519.6K
- Earning Date
- ELVA 08-12-2025
- IKT 08-13-2025
- Dividend Yield
- ELVA N/A
- IKT N/A
- EPS Growth
- ELVA N/A
- IKT N/A
- EPS
- ELVA N/A
- IKT N/A
- Revenue
- ELVA $48,016,000.00
- IKT N/A
- Revenue This Year
- ELVA $55.29
- IKT N/A
- Revenue Next Year
- ELVA $63.69
- IKT N/A
- P/E Ratio
- ELVA N/A
- IKT N/A
- Revenue Growth
- ELVA N/A
- IKT N/A
- 52 Week Low
- ELVA $1.67
- IKT $1.12
- 52 Week High
- ELVA $3.71
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- ELVA 50.37
- IKT 49.70
- Support Level
- ELVA $3.17
- IKT $1.56
- Resistance Level
- ELVA $3.53
- IKT $2.04
- Average True Range (ATR)
- ELVA 0.16
- IKT 0.15
- MACD
- ELVA -0.03
- IKT 0.02
- Stochastic Oscillator
- ELVA 28.26
- IKT 61.05
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.